Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. - Wikidata - awgldk - TriplyDB

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

http://www.wikidata.org/entity/Q48264845

about

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma New chemotherapy strategies and biological agents in the treatment of childhood ependymoma Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Recurrent Glioblastoma: Where we stand Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Dedifferentiation and reprogramming: origins of cancer stem cells Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications Diagnosis and treatment in neuro-oncology: an oncological perspective Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Brain tumor stem cells: Molecular characteristics and their impact on therapy Practical management of bevacizumab-related toxicities in glioblastoma Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Developmental and pathological angiogenesis in the central nervous system Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects In vitro enhancement of dendritic cell-mediated anti-glioma immune response by graphene oxide The future role of personalized medicine in the treatment of glioblastoma multiforme Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.Venous thromboembolism in malignant gliomas Angiogenic inhibition in high-grade gliomas: past, present and future.Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Bevacizumab for acute neurologic deterioration in patients with glioblastoma.Pros and cons of current brain tumor imaging

P2860

Q24293027-1CA4E10F-F265-48D9-A6E5-2286BF37CB45 Q24312100-3F6ABCC5-4AD4-4240-B2E6-439C4CCCDFA4 Q24564890-6EBDFA7E-71BC-4980-ACDE-50665783FE0D Q24615166-4D6EA5D0-A18B-4949-A037-8BC7E3DE5B22 Q24658324-C4ECD923-3103-4297-9187-0893D31FA794 Q26746067-4455C421-7912-4327-B28F-176D14D8C3E7 Q26752321-0BCA82F7-4F73-4CE3-B7B9-81C130C8F775 Q26765042-65FAF42F-21F5-495E-8E91-B9E67E88086A Q26785952-1166E402-886B-4751-91F5-ADA05D1882CD Q26824557-349FB00D-B0F2-4281-BD6A-422FF44A66D8 Q26826876-EF9416F3-2145-4A20-AE0C-09C2FC8B2343 Q26853308-528910D7-FC96-4EE8-965B-FF919F03A1F0 Q26853516-B56D02CE-9FB1-42A4-AE7F-D01361D5F1A3 Q26859056-CB5F8C6E-4167-4A58-8B1C-78DFA586C319 Q26860696-3C7B1FC8-3F0F-42C8-B39F-B06301B3EE91 Q27001560-F05B8A7C-D181-4252-B948-A975FA313A23 Q27003138-6D597CF2-AF84-4074-B2A3-17786E29F589 Q27015852-D69BD70E-5074-4AB8-8CEE-F6F8C864B5DB Q27021470-07046815-6D18-4017-9B90-7158FC6EFB12 Q27023250-784B3FD8-9E67-4237-A698-27DD9AA60C16 Q27024127-68026D83-1966-4D03-A47B-24F912CCD41F Q28073057-8252BF81-42A7-4A66-A3A9-9F6250B5B881 Q28116692-E1DDC593-B4CD-438C-A1A9-933473F93BD0 Q28389458-CD38D683-7DCA-4544-B5BE-D1C262EE737A Q28391635-15886CB6-6EA0-48B2-9F91-014BF43B83D6 Q28472048-6F59AC5F-6492-4CF2-96BB-3E0BCA243BA9 Q28749488-F7ACF36D-72EF-4A18-A65F-37888230BCE8 Q30300986-59A4DA8E-BBBF-47D4-9364-7FA018AF4538 Q30412393-68315F7C-1189-4A85-ACB8-6136C68444DC Q30417015-F32707B6-DB93-4C95-BAB4-9D65FD6F9431 Q30427266-D17994B2-660A-40C9-9EBA-62890D3F263D Q30429169-4797755D-E7A4-488B-8271-85D988B75BEF Q30436810-4A156E65-C716-4A2D-BE28-D3F062A90440 Q30455596-9680F0D3-88EF-4194-BAFA-5597265D8F40 Q30575110-0032F11F-1183-4FC8-98C3-C33DB02C4497 Q30607148-4CE18D0D-1AA7-4199-A128-57F25E288580 Q30616602-1CFE8102-0A1A-4A91-A8D0-93D7954D87F0 Q30708866-82DCB10F-5FC4-4209-B3A1-37179D385170 Q30838127-72253156-9CF6-46F0-96B4-9A2881E65427 Q30860126-C3628061-104C-45CE-A754-0F55ED717BB8

P2860

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

http://www.wikidata.org/entity/Q48264845

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@en

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@nl

type

label

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@en

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@nl

prefLabel

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@en

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@nl

P1433

Q48264845-E0EE288B-C16D-42AB-B1BB-F835E36FE08C

P1476

Q48264845-115A6FB1-2DC1-47F3-95DA-A988489BAF93

P2093

Q48264845-03D15468-511E-49B9-9BF1-A1106C8D094C

Q48264845-061532F5-F37A-4F9A-8CC8-CE9EB324FB72

Q48264845-0B715FE3-C542-42AA-8757-4CC07913832A

Q48264845-1A31227E-94FF-4EDC-920C-FDD77FEC463A

Q48264845-22EB4202-6992-41BE-88AC-C7EC235BFF98

Q48264845-4101405F-98A8-4F0F-A70D-1C400538B57A

Q48264845-BF559204-F581-4F67-B546-CBD30262E8E4

P304

Q48264845-F9490257-6A40-4412-AB88-C5A38FD4E6D2

P31

Q48264845-9A46F32C-B02E-4CDB-A740-2EBA13580417

P356

Q48264845-66BA2A4F-4C46-407F-A642-D4051AC3CBE8

P407

Q48264845-66A0DE8A-9BDF-4412-BCBA-EC020CD8E25C

P433

Q48264845-454AE72C-49DB-49B0-9D1D-67AEA290A76C

P478

Q48264845-A3D16CFB-1924-4527-8E17-720AF512DFC0

P50

Q48264845-279137DE-A8A3-4EE3-86EB-4BE647E8A558

Q48264845-3D99708C-5C08-4794-AB24-0E36273FA72F

Q48264845-64FA72D2-4517-4961-AFCB-913B12DFA07A

Q48264845-748272B0-B8D1-42E3-A6D9-F0F7DA52F750

Q48264845-97BBB388-6633-4717-B341-AB37AB76B819

Q48264845-F99B7DAB-25BC-45B8-B85B-896265C76D08

P577

Q48264845-FCACE09B-8A0D-46E7-8F97-B90FD81843C7

P698

Q48264845-CB2877F5-921C-446F-BC95-8ABA19D77091

P921

Q48264845-4C21CDF1-4E09-462F-B0F1-BEEAE20CC549

Q48264845-7AD754E1-7F6C-4952-8EB8-0F9E0400B34D

P356

1078-0432.CCR-06-2309

P1433

Clinical Cancer Research

P1476

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

@en

P2093

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jeannette M Dowell

http://www.w3.org/2001/XMLSchema#string

Jennifer A Quinn

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

Melissa Wagner

http://www.w3.org/2001/XMLSchema#string

Sith Sathornsumetee

http://www.w3.org/2001/XMLSchema#string

P304

1253-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-2309

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17317837

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial